Clinical trial
A Phase 1/2a Randomized, Double-masked, Placebo Controlled, Dose-ranging Study of the Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension
NCT03452033 is registered in ClinicalTrials.gov with Allysta Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2a Randomized, Double-masked, Placebo Controlled, Dose-ranging Study of the Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension
- Lead sponsor
- Allysta Pharmaceutical
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- March 15, 2018
- Completion date
- August 15, 2018
- Enrollment
- 87 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.